{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.63","upperLimit":"1.00","value":"0.86"},{"groupId":"OG001","lowerLimit":"0.18","upperLimit":"1.00","value":".43"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.63","upperLimit":"1.00","value":"0.86"},{"groupId":"OG001","lowerLimit":"0.02","upperLimit":"0.88","value":"0.14"}]}],"title":"24 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Progression Free Survival (PFS) defined as the time from the first day of study treatment to first documented disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 as a 20% increase in the sum of the longest diameter of target lesions, a measurable increase in a non-target lesion, or the appearance of new lesion(s).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1 (Cohort 1). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nCisplatin: Given IV\n\nDocetaxel: Given IV\n\nEtoposide: Given IV\n\nPembrolizumab: Given IV","id":"OG000","title":"Cohort 1: Metastatic or Locally Advanced Naive Small Cell Bladder Cancer"},{"description":"Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising etoposide IV on days 1-3, carboplatin IV on day 1, and docetaxel IV on day 1 (Cohort 2). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Cohort 2: Small Cell or Neuroendocrine Prostate Cancer"}],"paramType":"NUMBER","populationDescription":"Proportion of Participants with Progression Free Survival at 12 and 24 Months was measured using sample size of each cohort and incidence of events to provide confidence intervals.","reportingStatus":"POSTED","timeFrame":"12 months and 24 months.","title":"Proportion of Participants With Progression Free Survival at 12 and 24 Months","type":"PRIMARY","unitOfMeasure":"Proportion of patients"}